Genomic Health (NASDAQ: GHDX) and ELEKTA AB/ADR (OTCMKTS:EKTAY) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, risk, profitability, valuation and dividends.
ELEKTA AB/ADR pays an annual dividend of $0.08 per share and has a dividend yield of 0.6%. Genomic Health does not pay a dividend. ELEKTA AB/ADR pays out 200.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.
Genomic Health has a beta of 0.64, indicating that its stock price is 36% less volatile than the S&P 500. Comparatively, ELEKTA AB/ADR has a beta of 0.48, indicating that its stock price is 52% less volatile than the S&P 500.
Earnings and Valuation
This table compares Genomic Health and ELEKTA AB/ADR’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Genomic Health||$340.75 million||5.20||-$3.85 million||$0.01||5,011.00|
|ELEKTA AB/ADR||$1.23 billion||3.93||$14.30 million||$0.04||326.50|
ELEKTA AB/ADR has higher revenue and earnings than Genomic Health. ELEKTA AB/ADR is trading at a lower price-to-earnings ratio than Genomic Health, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
89.9% of Genomic Health shares are owned by institutional investors. Comparatively, 0.0% of ELEKTA AB/ADR shares are owned by institutional investors. 45.8% of Genomic Health shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
This table compares Genomic Health and ELEKTA AB/ADR’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of recent recommendations and price targets for Genomic Health and ELEKTA AB/ADR, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Genomic Health presently has a consensus target price of $33.29, suggesting a potential downside of 33.57%. Given Genomic Health’s higher possible upside, equities research analysts plainly believe Genomic Health is more favorable than ELEKTA AB/ADR.
About Genomic Health
Genomic Health, Inc., a healthcare company, provides actionable genomic information to personalize cancer treatment decisions worldwide. It develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions. The company offers the Oncotype DX invasive breast cancer test that is used for early stage invasive breast cancer patients to predict the breast cancer recurrence and chemotherapy benefit. It also provides the Oncotype DX colon cancer test, which is used to predict the likelihood of colon cancer recurrence in patients with stage II disease, as well as for use in patients with stage III disease treated with oxaliplatin-containing adjuvant therapy. In addition, the company provides the Oncotype DX tests for patients with ductal carcinoma in situ, a pre-invasive form of breast cancer; the Oncotype DX prostate cancer test, which provides a genomic prostate score to predict disease aggressiveness in men with low risk disease, as well as used to enhance treatment decisions for prostate cancer patients in conjunction with the Gleason score or tumor grading; and Oncotype DX AR-V7 Nucleus Detect test for men with metastatic castration-resistant prostate cancer. The company offers its products through a network of distributors. Genomic Health, Inc. has collaboration agreement with Epic Sciences, Inc.; license and development agreement with Biocartis N.V.; license agreement with Cleveland Diagnostics, Inc.; and a research collaboration agreement with Janssen Pharmaceuticals. The company was founded in 2000 and is based in Redwood City, California.
About ELEKTA AB/ADR
Elekta AB (publ) develops and sells clinical solutions for the treatment of cancer and brain disorders worldwide. The company offers Leksell Gamma Knife, a system for cranial stereotactic radiosurgery; the Extend system for utilization of Leksell Gamma Knife Perfexion; and Leksell Stereotactic System for neurosurgery and biopsies. Its neuroscience solutions comprise Gamma Knife radiosurgery for the treatment of brain disorders; stereotactic neurosurgery; and surgical navigation accessories, as well as Elekta Neuromag TRIUX, a magnetoencephalography platform. The company also provides oncology treatment solutions, such as Precise Treatment System, a digital treatment system; Elekta Axesse, a stereotactic radiation therapy system; Elekta Compact, a gateway to RT for oncology centers; Elekta Synergy system that visualizes tumor targets and normal tissue, and their movement between and during fractions; treatment planning systems; oncology information systems solutions; Versa HD, a linear accelerator; and Elekta Infinity system for volumetric arc modulated therapy, as well as various treatment techniques. In addition, it offers brachytherapy solutions that include afterloading platforms; real-time prostate solutions; Oncentra Brachy, a radiotherapy treatment planning system; Esteya for treating skin cancer; and applicators. Further, the company provides software products, including MOSAIQ oncology information system; Oncology Informatics/Data Alliances that streamlines the flow of information in the cancer care team; medical oncology software; Clarity Soft Tissue Visualization, a software for radiation therapy; Monaco, a treatment planning system; Venezia, an applicator for treating gynecological cancer; and METRIQ, a cancer registry data solution. It also offers installation, implementation, training, education, and consultative services. It primarily serves hospitals and academic institutions. The company was founded in 1972 and is headquartered in Stockholm, Sweden.
Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.